Compare TRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | RCKT |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.0M | 428.6M |
| IPO Year | 2002 | N/A |
| Metric | TRX | RCKT |
|---|---|---|
| Price | $1.77 | $4.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $1.70 | ★ $29.65 |
| AVG Volume (30 Days) | ★ 5.9M | 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $73.52 | N/A |
| Revenue Next Year | $109.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $2.19 |
| 52 Week High | $2.80 | $9.26 |
| Indicator | TRX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 75.06 |
| Support Level | $0.31 | $2.99 |
| Resistance Level | $1.87 | $8.26 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 42.39 | 76.33 |
TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.